Evidence map›Paper›PMID 41683536›Full record

ReviewMolecules (Basel, Switzerland)2026

Enhancing Tumor Photodynamic Therapy via Molecular Engineering and Functional Modification of Photosensitizers.

Wei Zheng, Linlin Tao, Xiaofeng Xia, Tianlin Wang, Feiyi Wang

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wei ZhengCollege of Chemistry and Chemical Engineering, Anshun University, Anshun 561000, China.
Linlin TaoHubei Key Laboratory of Drug Synthesis and Optimization, Jingchu University of Technology, Jingmen 448000, China.
Xiaofeng XiaHubei Key Laboratory of Drug Synthesis and Optimization, Jingchu University of Technology, Jingmen 448000, China.
Tianlin WangHubei Key Laboratory of Drug Synthesis and Optimization, Jingchu University of Technology, Jingmen 448000, China.ORCID 0009-0009-9823-7877
Feiyi WangHubei Three Gorges Laboratory, Yichang 443007, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photosensitizers are susceptible to interference from the biological internal environment, which largely restricts the clinical application of photodynamic therapy. For instance, most existing photosensitizers tend to aggregate in the biological environment, resulting in a decrease in reactive oxygen species yield; their therapeutic efficacy is unsatisfactory in hypoxic tumor environments; they are difficult to accumulate effectively in tumor sites and cannot accurately distinguish between tumors and healthy tissues. To address these issues, this review systematically elaborates on a series of optimization strategies, including improving the intersystem crossing efficiency of photosensitizers through molecular engineering, endowing them with aggregation-induced emission properties, developing type I photosensitizers, and functionalizing photosensitizers by modifying biological proteins, targeting groups, or combining with nanoengineering, aiming to enhance the efficiency of photodynamic therapy. By summarizing the latest research breakthroughs, innovative methods, and emerging applications in this field, the review provides practical solutions and broad application prospects for photodynamic therapy, which is expected to promote the clinical translation and application of photosensitizers.

Indexed as

NeoplasmsPhotochemotherapyPhotosensitizing AgentsAnimalsHumansReactive Oxygen SpeciesPhotosensitizing AgentsReactive Oxygen Speciesaggregation-induced emissionfunctionalizingphotodynamic therapyphotosensitizerstargeting groups

Identifiers

PMID41683536
PMCPMC12899708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.